COSM has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
COSM has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Cosmos Health's earnings per share without non-recurring items for the three months ended in Sep. 2023 was $-0.24. Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Sep. 2023 was $-4.32.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.
The historical rank and industry rank for Cosmos Health's EPS without NRI or its related term are showing as below:
Cosmos Health's EPS (Diluted) for the three months ended in Sep. 2023 was $-0.27. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Sep. 2023 was $-4.00.
Cosmos Health's EPS (Basic) for the three months ended in Sep. 2023 was $-0.27. Its EPS (Basic) for the trailing twelve months (TTM) ended in Sep. 2023 was $-4.00.
The historical data trend for Cosmos Health's EPS without NRI can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cosmos Health Annual Data | |||||||||||||||||||||
Trend | Jul13 | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | |||||||||||
EPS without NRI | Get a 7-Day Free Trial | -15.59 | -4.38 | -0.06 | -24.08 | -33.39 |
Cosmos Health Quarterly Data | ||||||||||||||||||||
Dec18 | Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | |
EPS without NRI | Get a 7-Day Free Trial | -1.57 | -3.64 | -0.23 | -0.22 | -0.24 |
For the Medical Distribution subindustry, Cosmos Health's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Medical Distribution industry and Healthcare sector, Cosmos Health's PE Ratio without NRI distribution charts can be found below:
* The bar in red indicates where Cosmos Health's PE Ratio without NRI falls into.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.
EPS without NRI for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-4.32
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cosmos Health (NAS:COSM) EPS without NRI Explanation
EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
Thank you for viewing the detailed overview of Cosmos Health's EPS without NRI provided by GuruFocus.com. Please click on the following links to see related term pages.
Grigorios Siokas | 10 percent owner | 5 AG. GEORGIOU STR., PILEA, THESSALONIKI J3 TK57001 |
Suhel Bhutawala | director | 141 WEST JACKSON BOULEVARD, SUITE 4236, CHICAGO IL 60604 |
Nikolaos Bardakis | officer: Chief Operating Officer | 141 WEST JACKSON BOULEVARD, SUITE 4236, CHICAGO IL 60604 |
Manfred Ziegler | director | 141 WEST JACKSON BOULEVARD, SUITE 4236, CHICAGO IL 60604 |
Anastasios Aslidis | director | 11 CANTERBURY LANE, WATCHUNG NJ 07069 |
Pavlos Ignatiades | officer: Chief Operating Officer | KALAPATHAKI 5, PANORAMA, THESSALONIKI J3 55236 |
Georgios Terzis | officer: Chief Financial Officer | 2 MELITOS STR., NEA SMIRNI, ATTICA J3 17121 |
Peter Goldstein | director | 151 NORTH NOB HILL ROAD SUITE 321, FORT LAUDERDALE FL 33324 |
John James Hoidas | director | 9301 S. HARLEM AVENUE, OAK LAWN, CHICAGO IL 60453 |
Dimitrios Goulielmos | director, 10 percent owner, officer: CEO | 141 WEST JACKSON BLVD, SUITE 4236, CHICAGO IL 60604 |
Panagiotis Tolis | director, officer: Secretary | PERICLEOUS 50 STREET, ATHENS J3 15232 |
Panagiotis Drakopoulos | director, 10 percent owner, officer: CEO | 200 SOUTH WACKER DRIVE, SUITE 300, CHICAGO IL 60606 |
Vasileios Mavrogiannis | director, 10 percent owner, officer: CFO | TERTSETI 23 STREET, KESARIANI J3 16122 |
From GuruFocus
By ACCESSWIRE • 09-22-2023
By ACCESSWIRE • 12-20-2023
By ACCESSWIRE • 10-11-2023
By ACCESSWIRE • 09-13-2023
By ACCESSWIRE • 10-05-2023
By ACCESSWIRE • 08-15-2023
By ACCESSWIRE • 01-18-2024
By ACCESSWIRE ACCESSWIRE • 06-16-2023
By ACCESSWIRE • 09-12-2023
By ACCESSWIRE • 12-18-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.